Diagnostic Microbiology & Infectious Disease
Volume 65, Issue 4 , Pages 414-426 , December 2009

Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999–2008)

  • Paul R. Rhomberg

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • ,
  • Ronald N. Jones

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • Tufts University School of Medicine, Boston, MA 02111, USA
    • Corresponding Author InformationCorresponding author. JMI Laboratories, North Liberty, IA 52317, USA. Tel.: +1-319-665-3370; fax: +1-319-665-3371.

Received 27 July 2009 ,Accepted 28 August 2009.

References 

  1. Aboufaycal H, Sader HS, Rolston K, Deshpande LM, Toleman M, Bodey G, et al. blaVIM-2 and blaVIM-7 carbapenemase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program. J. Clin. Microbiol. 2007;45:614–615
  2. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997–2006. Int. J. Antimicrob. Agents. 2009;34:82–85
  3. American Thoracic SocietyInfectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005;15:388–416
  4. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein. Antimicrob. Agents Chemother. 1997;41:563–569
  5. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin. Infect. Dis. 2004;39:55–60
  6. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 2005;165:1430–1435
  7. Cao VT, Arlet G, Ericsson BM, Tammelin A, Courvalin P, Lambert T. Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration. J. Antimicrob. Chemother. 2000;46:895–900
  8. Castanheira M, Mendes RE, Rhomberg PR, Jones RN. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical Centers: molecular evaluation from the MYSTIC Program (2007).. Microb. Drug Resist. 2008;14:211–216
  9. Clinical and Laboratory Standards Institute (CLSI) . Development of in vitro susceptibility testing criteria and quality control parameters—third edition, M23-A3. Wayne, PA: CLSI; 2008;
  10. Clinical and Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial disk susceptibility tests; approved standard—10th edition, M02-A10. Wayne, PA: CLSI; 2009;
  11. Clinical and Laboratory Standards Institute (CLSI) . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—eighth edition, M07-A8. Wayne, PA: CLSI; 2009;
  12. Clinical and Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19). Wayne, PA: CLSI; 2009;
  13. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002–2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann. Pharmacother. 2009;43:220–227
  14. Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999–2005). Diagn. Microbiol. Infect. Dis. 2006;56:367–372
  15. EARSS . European Antimicrobial Surveillance System. Available at http://www.rivm.nl/earss/about2007;Accessed October 25, 2007
  16. Edwards JR. Meropenem: a microbiological overview. J. Antimicrob. Chemother. 1995;36(Suppl. A):1–17
  17. Felmingham D, White AR, Jacobs MR, Appelbaum PC, Poupard J, Miller LA, et al. The Alexander Project: the benefits from a decade of surveillance. J. Antimicrob. Chemother. 2005;56(Suppl. 2):ii3–ii21
  18. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE, Archibald LK, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals.. Clin. Infect. Dis. 1999;29:245–252
  19. Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA, Jones RN. Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f beta-lactamase (SME-1) in the United States: results from the MYSTIC Programme. Diagn. Microbiol. Infect. Dis. 2001;39:125–127
  20. Harding I, Felmingham D. PROTEKT years 1–3 (1999–2002): study design and methodology. J. Chemother. 2004;16(Suppl. 6):9–18
  21. Hossain A, Ferraro MJ, Pino RM, Dew RB, Moland ES, Lockhart TJ, et al. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob. Agents Chemother. 2004;48:4438–4440
  22. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control. Hosp. Epidemiol. 2009;30:666–671
  23. Jones RN. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance.. Diagn. Microbiol. Infect. Dis. 1996;25:153–161
  24. Jones RN. Detection of emerging resistance patterns within longitudinal surveillance systems: data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. J. Antimicrob. Chemother. 2000;46(Suppl. T2):1–8
  25. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997–2001). Semin. Respir. Crit. Care Med. 2003;24:121–134
  26. Jones RN, Masterton R. Determining the value of antimicrobial surveillance programs. Diagn. Microbiol. Infect. Dis. 2001;41:171–175
  27. Jones RN, Pfaller MA. Ciprofloxacin as broad-spectrum empiric therapy—are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?. Diagn. Microbiol. Infect. Dis. 2002;42:213–215
  28. Jones RN, Rhomberg PR, Varnam DJ, Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: initial studies for the MYSTIC programme in India. Int. J. Antimicrob. Agents. 2002;20:426–431
  29. Jones RN, Deshpande L, Fritsche TR, Sader HS. Determination of epidemic clonality among multidrug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999–2003). Diagn. Microbiol. Infect. Dis. 2004;49:211–216
  30. Jones RN, Mendes C, Turner PJ, Masterton R. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997–2004. Diagn. Microbiol. Infect. Dis. 2005;53:247–256
  31. Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagn. Microbiol. Infect. Dis. 2008;61:203–213
  32. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 2003;43:1116–1123
  33. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob. Agents Chemother. 2004;48:2464–2470
  34. Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned.. Arch. Intern. Med. 2002;162:1515–1520
  35. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. 2006;46:1171–1178
  36. Masterton RG. Surveillance studies: how can they help the management of infection?. J. Antimicrob. Chemother. 2000;46(Suppl. T2):53–58
  37. Mathai D, Rhomberg PR, Biedenbach DJ, Jones RN. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn. Microbiol. Infect. Dis. 2002;44:367–377
  38. Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother. 2003;47:1297–1300
  39. Mutnick AH, Rhomberg PR, Sader HS, Jones RN. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999–2001). J. Antimicrob. Chemother. 2004;53:290–296
  40. Package Insert . Merrem. Wilmington, DE: AstraZeneca Pharmaceuticals; 2007;
  41. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin. Microbiol. Infect. 2000;6:460–463
  42. Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated world wide. Diagn. Microbiol. Infect. Dis. 1997;28:157–163
  43. Pfaller MA, Jones RN. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). J. Antimicrob. Chemother. 2000;46(Suppl. T2):25–37
  44. Pfaller MA, Jones RN, Biedenbach DJ. Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). Diagn. Microbiol. Infect. Dis. 2001;41:177–182
  45. Queenan AM, Torres-Viera C, Gold HS, Carmeli Y, Eliopoulos GM, Moellering RC, et al. SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob. Agents Chemother. 2000;44:3035–3039
  46. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC Program report from the United States component (2005). Diagn. Microbiol. Infect. Dis. 2007;57:207–215
  47. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Antibiotic resistance in hospitalized patients: MYSTIC Program (1999–2002). Antibiot. Clin. 2003;7:2–7
  48. Rhomberg PR, Jones RN, Sader HS. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres. Int. J. Antimicrob. Agents. 2004;23:52–59
  49. Rhomberg PR, Jones RN, Sader HS, Fritsche TR. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). Diagn. Microbiol. Infect. Dis. 2004;49:273–281
  50. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J. Chemother. 2005;17:459–469
  51. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn. Microbiol. Infect. Dis. 2006;56:57–62
  52. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection Surveillance Program in the United States. Diagn. Microbiol. Infect. Dis. 2006;54:249–257
  53. Rhomberg PR, Deshpande LM, Kirby JT, Jones RN. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006). Diagn. Microbiol. Infect. Dis. 2007;59:425–432
  54. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.. J. Antimicrob. Chemother. 2009;64:142–150
  55. Senda K, Arakawa Y, Ichiyama S, Nakashima K, Ito H, Ohsuka S, et al. PCR detection of metallo-beta-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum beta-lactams. J. Clin. Microbiol. 1996;34:2909–2913
  56. Senda K, Arakawa Y, Nakashima K, Ito H, Ichiyama S, Shimokata K, et al. Multifocal outbreaks of metallo-beta-lactamase–producing Pseudomonas aeruginosa resistant to broad-spectrum beta-lactams, including carbapenems. Antimicrob. Agents Chemother. 1996;40:349–353
  57. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 2008;46:155–164
  58. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 1995;33:2233–2239
  59. Toleman MA, Rolston K, Jones RN, Walsh TR. blaVIM-7, an evolutionarily distinct metallo-beta-lactamase gene in a Pseudomonas aeruginosa isolate from the United States. Antimicrob. Agents Chemother. 2004;48:329–332
  60. Turner PJ. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview. J Antimicrob Chemother. 2000;46(Suppl. T2):9–23
  61. Turner PJ. Susceptibility of meropenem and comparators tested against 30,634 Enterobacteriaceae isolated in the MYSTIC Programme (1997–2003). Diagn. Microbiol. Infect. Dis. 2004;50:291–293
  62. Turner PJ. Use of a program-specific website to disseminate surveillance data obtained from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Study. Diagn. Microbiol. Infect. Dis. 2005;53:273–279
  63. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn. Microbiol. Infect. Dis. 2009;63:217–222
  64. Turner PJ, Greenhalgh JM, Edwards JR, McKellar J. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) programme. Int. J. Antimicrob. Agents. 1999;13:117–125
  65. Wisemann LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1995;50:73–101
  66. Woodford N, Tierno PM, Young K, Tysall L, Palepou MF, Ward E, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center.. Antimicrob. Agents Chemother. 2004;48:4793–4799
  67. Woodford N, Hill RL, Livermore DM. In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J. Antimicrob. Chemother. 2007;59:582–583
  68. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2001;45:1151–1161

PII: S0732-8893(09)00362-9

doi: 10.1016/j.diagmicrobio.2009.08.020

Diagnostic Microbiology & Infectious Disease
Volume 65, Issue 4 , Pages 414-426 , December 2009

Article Tools

* Image Usage & Resolution